Articles

New data from a phase 3 study evaluating SGX301 for treatment of cutaneous T-cell lymphoma (CTCL) skin symptoms was recently presented at the American Academy of Dermatology Virtual Meeting Experience (AAD VMX 2021).

Study: SGX301 Demonstrates Efficacy for Treatment of Cutaneous T-cell Lymphoma

Videos

In this video interview, Melissa Stenstrom, MD, discusses how physicians can promote the use of sun protection and regular skin cancer screenings to help prevent skin cancer among their patients.

Preventing Skin Cancer Through Sun Protection

A survey from the American Academy of Dermatology found that younger generations lack skin cancer knowledge. 

AAD Finds One Third of American’s Fail Quiz on Skin Cancer

Artificial intelligence diagnostics are less accurate on skin of color than light skin, even when trained on equal numbers of images.

AI Diagnostics Fall Short in Skin of Color 

In part 2 of this skin cancer report from the American Academy of Dermatology Virtual Meeting Experience 2021 (AAD VMX), an expert shares pearls on regular medication reviews.

Tips to Improve High-Risk Skin Cancer Management

More detailed tumor classifications, patient data advance surveillance strategies for the high-risk patient population.

Step up Surveillance Strategies for Skin Cancer

Podcasts

With the summer months quickly  approaching, we’re discussing the importance of skin cancer screenings, as well as encouraging regular sun protection usage among patients. This episode also touches on the role of telemedicine in skin cancer screenings, top product recommendations for sun protection and tips on managing patient expectations if the patient is diagnosed with skin cancer.  


The Cutaneous Connection: Episode 22- The Role of Sun Protection in Skin Cancer Prevention

Todd Schlesinger, MD, FAAD, outlines his research on newly FDA-approved topical tirbanibulin (Klisyri, Almirall) for treatment of actinic keratosis (AK), as well as compares it to another topical treatment for AK, 5-fluorouracil.

Tirbanibulin Compared to 5-Fluorouracil for Treatment of Actinic Keratosis

Single-agent pembrolizumab yielded robust antitumor activity in patients with locally advanced or recurrent/metastatic cutaneous squamous cell carcinoma.

Pembrolizumab Demonstrates Robust Activity in Advanced and Recurrent/Metastatic CSCC

Biofrontera announces it is seeking FDA-approval for its new BF-RhodoLED XL lamp to be used in combination with topical aminolevulinic acid hydrochloride gel 10% for the treatment of actinic keratosis.

Skin Cancer (Nonmelanoma)